title: Use of nuclear magnetic resonance-based metabolomics in detecting drug resistance in cancer.
abstract: Cancer cells possess a highly unique metabolic phenotype, which is characterized by high glucose uptake, increased glycolytic activity, decreased mitochondrial activity, low bioenergetic and increased phospholipid turnover. These metabolic hallmarks can be readily assessed by metabolic technologies - either in vitro or in vivo - to monitor responsiveness and resistance to novel targeted drugs, where specific inhibition of cell proliferation (cytostatic effect) occurs rather than direct induction of cell death (cytotoxicity). Using modern analytical technologies in combination with statistical approaches, 'metabolomics', a global metabolic profile on patient samples can be established and validated for responders and nonresponders, providing additional metabolic end points. Discovered metabolic end points should be translated into noninvasive metabolic imaging protocols.
authors.affiliation: Cancer Center Metabolomics NMR Core, University of Colorado, CO, USA.
authors.forename: Andrea L
authors.initials: AL
authors.lastname: Merz
authors.forename: Natalie J
authors.initials: NJ
authors.lastname: Serkova